More than 150 representatives from patient organizations, industry, academia, and the world of regulation met in Warsaw...
More than 150 representatives from patient organizations, industry, academia and the world of regulation met in Warsaw today to plan the next stage of an ambitious European project aimed at increasing the involvement of patients in the development of new medicines.
At the heart of their discussions was the devising of a strategy to reach at least 100,000 European citizens with an interest in health. The idea is to equip them with information and tools to understand how the development process works – and perhaps motivate them to become more involved in it.
The workshop was held by the European Patients' Academy, known as EUPATI, funded by Innovative Medicines Initiative, a partnership of the European Commission with the European Federation of Pharmaceutical Industries and Associations (EFPIA).
The scene was set by Anna Zawada from Poland's Agency for Health Technology Assessment. Patient involvement is written into the agency's operating principles, she said. But in practice, it can be hard to find patients with sufficient expertise and confidence to fill the roles assigned to them.
Anna Zawada's introduction was followed by the first public presentation of EUPATI-sponsored research into public knowledge of and attitudes to medicines development across Europe.
Bella Starling from the University of Manchester and the UK NHS's Central Manchester University Hospitals revealed – perhaps predictably – low levels of knowledge of medicines development across Europe, including about how patients can contribute to the process. But there is also considerable public interest in the area, though accompanied by a lack of trust in the authorities and the industry in some countries.
The research evidence will underpin EUPATI as it develops its plans to communicate with the health-interested public. Those plans will be supplemented by suggestions made at the workshop – and by some of the more than 700 live Tweets coming in to the workshop at #eupati2014.
Top of the list of suggestions is the growing importance of social media as a way of reaching the public generally, especially the young and people with reduced levels of literacy. "We need to be open to the possibilities of technology, not fearful," said Nicola Bedlington from the European Patients' Forum.
The lynchpin of the plan to engage hundreds of thousands of Europeans will be EUPATI's new Internet Library. Project director Jan Geissler explained that this will come online towards the end of 2015, and will be available in seven European languages – English, French, Spanish, Italian, German, Polish and Russian.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.